Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 5/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.37 |
| ▸ | FURIN | P09958 | 2/20 | 0.35 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.35 |
| ▸ | NPY1R | P25929 | 2/20 | 0.34 |
| ▸ | NPY4R | P50391 | 2/20 | 0.34 |
| ▸ | GLP1R | P43220 | 3/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21570028 | 1.00 | FAP (0.39) | FAPOPRK1FURINMAP1LC3BNPY1R | |
| SCHEMBL24898929 | 1.00 | FAP (0.39) | FAPOPRK1FURINMAP1LC3BNPY1R | |
| SCHEMBL22702620 | 1.00 | FAP (0.39) | FAPOPRK1FURINMAP1LC3BNPY1R | |
| SCHEMBL30483105 | 1.00 | FAP (0.39) | FAPOPRK1FURINMAP1LC3BNPY1R | |
| SCHEMBL21570074 | 0.94 | FAP (0.39) | FAPOPRK1FURINMAP1LC3BNPY1R | |
| SCHEMBL24224636 | 0.94 | FAP (0.40) | FAPOPRK1FURINMAP1LC3BNPY1R | |
| SCHEMBL23943282 | 0.94 | FAP (0.40) | FAPOPRK1FURINMAP1LC3BNPY1R | |
| SCHEMBL22138625 | 0.94 | FAP (0.40) | FAPOPRK1FURINMAP1LC3BNPY1R | |
| SCHEMBL25450085 | 0.94 | FAP (0.40) | FAPOPRK1FURINMAP1LC3BNPY1R | |
| SCHEMBL16946352 | 0.94 | FAP (0.40) | FAPOPRK1FURINMAP1LC3BNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026098621-A1 | ENGINEERED ANTIBODY WITH SITE-SPECIFIC CONJUGATION, ANTIBODY-DRUG CONJUGATE, AND APPLICATION THEREOF | 百力司康生物医药(杭州)有限公司 | 2026-05-15 | — | — | WO | claimed |
| US-12605457-B2 | Modified EGFR antibody with reduced affinity, drug conjugate, and use thereof | Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (CN) | 2026-04-21 | — | — | US | claimed |
| US-20240075154-A1 | ENGINEERED ANTIBODY, ANTIBODY-DRUG CONJUGATE, AND USE THEREOF | BLISS BIOPHARMACEUTICAL HANGZHOU CO LTD (CN) | 2024-03-07 | — | — | US | claimed |
| US-20240009318-A1 | MODIFIED EGFR ANTIBODY WITH REDUCED AFFINITY, DRUG CONJUGATE, AND USE THEREOF | BLISS BIOPHARMACEUTICAL HANGZHOU CO LTD (CN) | 2024-01-11 | — | — | US | claimed |
| US-20240002527-A1 | ANTI-CD73 ANTIBODY, ANTIBODY-DRUG CONJUGATE, AND USE THEREOF | BLISS BIOPHARMACEUTICAL HANGZHOU CO LTD (CN) | 2024-01-04 | — | — | US | claimed |
| US-20230414781-A1 | ANTI-CD276 ANTIBODY, ANTIBODY-DRUG CONJUGATE, AND USE THEREOF | BLISS BIOPHARMACEUTICAL HANGZHOU CO LTD (CN) | 2023-12-28 | — | — | US | claimed |
| EP-4247855-A1 | ANTI-CD73 ANTIBODY, ANTIBODY-DRUG CONJUGATE, AND USE THEREOF | Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (CN) | 2023-09-27 | — | — | EP | claimed |
| EP-4247853-A1 | MODIFIED EGFR ANTIBODY WITH REDUCED AFFINITY, DRUG CONJUGATE, AND USE THEREOF | Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (CN) | 2023-09-27 | — | — | EP | claimed |
| EP-4247854-A1 | ANTI-CD276 ANTIBODY, ANTIBODY-DRUG CONJUGATE, AND USE THEREOF | Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (CN) | 2023-09-27 | — | — | EP | claimed |
| EP-4247425-A1 | ENGINEERED ANTIBODY, ANTIBODY-DRUG CONJUGATE, AND USE THEREOF | Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (CN) | 2023-09-27 | — | — | EP | claimed |
| WO-2022105873-A1 | ENGINEERED ANTIBODY, ANTIBODY-DRUG CONJUGATE, AND USE THEREOF | Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (CN) | 2022-05-27 | — | — | WO | claimed |
| WO-2022105881-A1 | ANTI-CD73 ANTIBODY, ANTIBODY-DRUG CONJUGATE, AND USE THEREOF | Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (CN) | 2022-05-27 | — | — | WO | claimed |
| WO-2022105878-A1 | MODIFIED EGFR ANTIBODY WITH REDUCED AFFINITY, DRUG CONJUGATE, AND USE THEREOF | Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (CN) | 2022-05-27 | — | — | WO | claimed |
| WO-2022105879-A1 | ANTI-CD276 ANTIBODY, ANTIBODY-DRUG CONJUGATE, AND USE THEREOF | Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (CN) | 2022-05-27 | — | — | WO | claimed |
| WO-2026098621-A1 | ENGINEERED ANTIBODY WITH SITE-SPECIFIC CONJUGATION, ANTIBODY-DRUG CONJUGATE, AND APPLICATION THEREOF | 百力司康生物医药(杭州)有限公司 | 2026-05-15 | — | — | WO | disclosed |
| EP-4727592-A1 | CONJUGATED MOLECULES | Valink Therapeutics Ltd (GB) | 2026-04-22 | — | — | EP | disclosed |
| US-12605457-B2 | Modified EGFR antibody with reduced affinity, drug conjugate, and use thereof | Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (CN) | 2026-04-21 | — | — | US | disclosed |
| US-20190153107-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC. (US) | 2019-05-23 | — | — | US | disclosed |
| EP-3468993-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| US-20170182179-A1 | Antibody Drug Conjugates with Cell Permeable BCL-XL Inhibitors | ABBVIE INC. (US) | 2017-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605457-B2 | Modified EGFR antibody with reduced affinity, drug conjugate, and use thereof | EGFR, ERBB2, IGSF11 | FAP 4822/4885OPRK1 1663/4885FURIN 4838/4885 |
| US-20170182179-A1 | Antibody Drug Conjugates with Cell Permeable BCL-XL Inhibitors | BCL2, BCL2L10, BAX | FAP 3670/4885OPRK1 4493/4885FURIN 4004/4885 |
| US-20190153107-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | FAP 4493/4885OPRK1 3630/4885FURIN 2449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.